Explore All 789 Divestiture Life Science Deals - Search the Database Free
M&A Deal Summary |
|
|---|---|
| Date | March 4, 2024 |
| Target | Cimerli |
| Sector | Life Science |
| Buyer(s) | Sandoz International |
| Sellers(s) | Coherus Biosciences |
| Deal Type | Divestiture |
| Deal Value | 170M USD |
FILTER BY
Sandoz International GmbH is a developer, manufacturer and markets generic pharmaceutical products focused on biosimilars, injectables, inhalers and transdermal patches.
| Deal Context for Buyer | # |
|---|---|
| Overall | 5 of 5 |
| Sector: Life Science | 4 of 4 |
| Type: Divestiture | 4 of 4 |
| State: California | 1 of 1 |
| Country: United States | 2 of 2 |
| Year: 2024 | 1 of 1 |
| Size (of disclosed) | 4 of 4 |
| DATE | TARGET | DEAL TYPE | VALUE |
|---|---|---|---|
| 2021-02-11 |
GSK - Cephalosporin Antibiotics Business
Brentford, United Kingdom GSK's Cephalosporin Antibiotics Business is a provider of antibiotics used to treat a range of bacterial infections. |
Buy | $500M |
| Category | Company |
|---|---|
| Founded | 2010 |
| Sector | Life Science |
| Employees | 228 |
| Revenue | 267M USD (2024) |
Coherus Biosciences is a biotechnology company focused on developing products. Coherus BioSciences was founded in 2010 and is based in Redwood City, California.
| Deal Context for Seller | # |
|---|---|
| Overall | 1 of 2 |
| Sector: Life Science | 1 of 2 |
| Type: Divestiture | 1 of 2 |
| State: California | 1 of 2 |
| Country: United States | 1 of 2 |
| Year: 2024 | 1 of 1 |
| Size (of disclosed) | 1 of 1 |
| DATE | TARGET | DEAL TYPE | VALUE |
|---|---|---|---|
| 2023-06-16 |
Surface Oncology
Cambridge, Massachusetts, United States Surface Oncology is an immuno-oncology company developing next-generation antibody therapies focused on the tumor microenvironment. Its pipeline includes two wholly-owned programs: SRF388, a Phase 2 program targeting IL-27, and SRF114, a Phase 1 program that selectively depletes regulatory T cells in the tumor microenvironment via targeting CCR8. Surface Oncology was founded in 2014 and is based in Cambridge, Massachusetts. |
Buy | $65M |
| DATE | TARGET | DEAL TYPE | VALUE |
|---|---|---|---|
| 2025-04-14 |
Udenyca
Redwood City, California, United States Udenyca (pegfilgrastim-cbqv) is a leukocyte growth factor indicated to decrease the incidence of infection, as manifested by febrile neutropenia, in patients with non-myeloid malignancies receiving myelosuppressive anti-cancer drugs associated with a clinically significant incidence of febrile neutropenia. It increases survival in patients acutely exposed to myelosuppressive doses of radiation (Hematopoietic Subsyndrome of Acute Radiation Syndrome). |
Sell | - |
